Immunomedics, Inc. (IMMU) News
Filter IMMU News Items
IMMU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IMMU News From Around the Web
Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.
Gilead Makes A Sizeable Bet On ImmunomedicsTrodelvy. Source: Fierce Pharma Gilead (GILD) just unpacked part of its $21 billion war chest to acquire Immunomedics (IMMU) for $21 billion. "The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate ((ADC)) that was granted accelerated approval by the U.S. Food and Drug Administration... |
Immunomedics' trodelvy shows 27% response rate in urothelial cancerImmunomedics (IMMU) announced positive results from cohort 1 (n=113) of cisplatin-eligible patients in Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC).Results confirmed the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC... |
Immunomedics Trodelvy extends survival benefit in late-stage triple-negative breast cancer studyImmunomedics (IMMU) announces results from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) compared to treatment of choice ((TPC)) standard single-agent chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC) who had previously received at least two prior therapies for metastatic disease. These results were presented at the ESMO Virtual... |
The Week Ahead In Biotech: Conference Presentations, IPOs In The MixBiotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here're the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual ... |
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain CancersResults include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) |
Wachtell regains top M&A perch, leapfrogging Latham for nowWith the fourth quarter fast approaching, Wachtell, Lipton, Rosen & Katz has passed Latham & Watkins to once again become the top U.S. M&A adviser based on transaction value for 2020, after advising biotech company Immunomedics Inc on its agreement to be acquired by Gilead… |
The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPOScaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ... |
What will it take for Gilead to break even on its $21 billion deal?The deal, which gives Gilead control of Immunomedics, came at a more than 100% premium to the latter firm's most recent stock price. |
Immunomedics, Cassava Sciences leads gainers pack, Nano-X Imaging, Teligent among major losersGainers: Immunomedics (IMMU) +101%, Cassava Sciences, (SAVA) +78%, Vaxart (VXRT) +28%, Mersana Therapeutics (MRSN) +17%, Venus Concept (VERO) +15%.Losers: Nano-X Imaging (NNOX) -14%, Teligent (TLGT) -12%, Mallinckrodt (MNK) -12%, Kala Pharmaceuticals (KALA) -12%, Co-Diagnostics (CODX) -11%.... |
VXRT, IMMU, GRPN and CODX among midday moversGainers: Immunomedics (IMMU) +100%.Cassava Sciences (SAVA) +86%.Vaxart (VXRT) +48%.Scientific Games (SGMS) +44%.Mersana Therapeutics (MRSN) +25%.Evogene (EVGN) +24%.Select Energy Services (WTTR) +23%.NextDecade (NEXT) +20%.Trevena (TRVN) +20%.DiamondPeak (DPHC) +20%.Losers: Nano-X Imaging (NNOX) -15%.Teligent (TLGT) -13%.Co-Diagnostics (CODX) -13%.Groupon (GRPN) -12%.9F (JFU) -12%.OneWater Marine (ONEW) -12%.Kala Pharmaceuticals (KALA) -11%.Goosehead Insurance (GSHD) -11%.Salem Media (SALM) -9%.Astrotech (ASTC) -9%.... |